Diagnosis and treatment of esthesioneuroblastoma

doi:10.3760/cma.j.issn.1673-422X.2014.05.006

Abstract

Abstract: Esthesioneuroblastoma is one of the most uncommon nasal malignancies which is characterized by low incidence and high misdiagnosis rate. The only prognosis factor is the metastasis on lymph node of neck. Its clinical symptoms are associated with tumor infiltrating extent. Pathological diagnosis is the “gold standard” on esthesioneuroblastoma, and the Kadish staging based on the image is the most important staging standard. The traditional operation therapy mode has been replaced by the combined method of operation and radiotherapy, with the adjunctive therapy of chemotherapy.

Key words: Olfactory nerve, Neuroblastoma, Diagnosis, Therapy

Li Guangxin, Shu Xin, Li Gong, Gou Miaomiao. Diagnosis and treatment of esthesioneuroblastoma[J]. Journal of International Oncology, 2014, 41(5): 338-341.

References

［1］ Aggarwal SK, Kumar R, Shrivastav A, et al. Esthesioneuroblastoma presenting with proptosis and bilateral neck metastasis: an unusual presentation［J］. J Pediatr Neurosci, 2011, 6(1):78-81. ［2］ Bisogno G, Soloni P, Conte M, et al. Esthesioneuroblastoma in pediatric and adolescent age. A report from the TREP project in cooperation with the Italian Neuroblastoma and Soft Tissue Sarcoma Committees［J］. BMC Cancer, 2012, 12:117. ［3］ Majchrzak E, Wegner A, Golusiński W. Diagnostic difficulties of the patient with sinonasal tract tumor; therapeutic dilemmasa case report and up to date review ［J］. Otolaryngol Pol, 2011, 65(5):377-382. ［4］ Gallia GL, Reh DD, Lane AP, et al. Endoscopic resection of esthesioneuroblastoma ［J］. J Clin Neurosci, 2012, 19(11):1478-1482. ［5］ Ward PD, Heth JA, Thompson BG, et al. Esthesioneuroblastoma: results and outcomes of a single institution′s experience［J］. Skull Base, 2010, 19(2):133-140. ［6］ Kane AJ, Sughrue ME, Rutkowski MJ, et al. Posttreatment prognosis of patients with esthesioneuroblastoma［J］. J Neurosurg, 2010, 113(2):340-351. ［7］ Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results［J］. Arch Otolaryngol Head Neck Surg, 2009, 135(12):1219-1224. ［8］ Damar M, Baserer N, Ozkara S, et al. Late neck metastasis in esthesioneuroblastoma: a case report［J］. Kulak Burun Boqaz Ihtis Derg, 2012, 22(4):228-231. ［9］ Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16year metaanalysis of 361 patients［J］. Laryngoscope, 2009, 119(7):1412-1416. ［10］ Bak M, Wein RO. Esthesioneuroblastoma: a contemporary review of diagnosis and management［J］. Hematol Oncol Clin Norht Am, 2012, 26(6):1185-1207. ［11］ Hojo H, Zenda S, Akimoto T, et al. Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies［J］. J Radiat Res, 2012, 53(5):704-709. ［12］ Nichols AC, Chan AW, Curry WT, et al. Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy［J］. Skull Base, 2008, 18(5):327-337. ［13］ Bachar G, Goldstein DP, Shah M, et al. Esthesioneuroblastoma: the princess margaret hospital experience［J］. Head Neck, 2008, 30(12):1607-1614. ［14］ Jiang GY, Li FC, Chen WK, et al. Therapy and prognosis of intracranial invasive olfactory neuroblastoma［J］. Otolaryngol Head Neck Srug, 2011, 145(6):951-955. ［15］ Platek ME, Merzianu M, Mashtare TL, et al. Improved sruvival following srugery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database［J］. Radiat Oncol, 2011, 6:41. ［16］ Ozsahin M, Gruber G, Olszyk O, et al. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study［J］. Int J Radiat Oncol Biol Phys, 2010, 78(4):992-997. ［17］ Gupta S, Husain N, Sundar S. Esthesioneuroblastoma chemotherapy and radiotherapy for extensive disease: a case report［J］. World J Surg Oncol, 2011, 9:118.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[9]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[10]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[11]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[12]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[13]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[14]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[15]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.